Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

BIPRETERAX 8 MG/2,5 MG COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/BIPRETERAX 8 MG/2,5 MG COMPRIMIDOS

Approved

STANDARD

BIPRETERAX 8 MG/2,5 MG COMPRIMIDOS

Anpharm Przedsiebiorstwo Farmaceutyczne S.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Oct 27, 2023
Approval ID: 5fc00c2e640b78a1
Company: Anpharm Przedsiebiorstwo Farmaceutyczne S.A.
Type: Standard

Approval Details

Approval Id: 5fc00c2e640b78a1
Drug Cima Aemps Name: BIPRETERAX 8 MG/2,5 MG COMPRIMIDOS
Register Number: OGYI-T-6831-02IP2
Holder Company Name: Anpharm Przedsiebiorstwo Farmaceutyczne S.A.
Marketing Company Name: Euromed Pharma Spain S.L.
Authorization Date: 2023-10-27
Dosage Form: COMPRIMIDO
Dose: 8 mg/2,5 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Anpharm Przedsiebiorstwo Farmaceutyczne S.A.

Active Ingredients

PERINDOPRIL ERBUMINA

8 mg

INDAPAMIDA

2,5 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Oct 27, 2023

Approval ID

5fc00c2e640b78a1

Type

Standard

Back to CIMA-AEMPS Approvals